PRQR ProQR Therapeutics NV

6.350.05 (+0.71%)
IEX real time price: 1:28:26 PM

Quote

Previous Close
-
Day Range
-
52 Week Range
$5.62-$24.00
Volume
72,321
Avg Volume
191,563
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$246.65M
Enterprise Value (EV)
$132.25M
PE Ratio
-
EV/EBITDA
-2.73
Price/Sales
-
Price/Book
2.31
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-$1.12M
EBITDA
-$48.49M
EPS, ttm
-$1.34
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
12/2/2019 (48 days)
Debt to Equity
8%
Debt
$6.29M
Cash
$120.69M
Net Debt
-

Performance

Beta
0.76
200 Day Moving Avg
$11.29
50 Day Moving Avg
$7.24
52 Week Change
-63.94%
YTD Change
-63.24%
1 Month Change
-12.50%
3 Month Change
-29.61%
6 Month Change
-51.54%
1 Year Change
-63.94%
2 Year Change
41.57%
5 Year Change
-46.70%

Share Count

Shares Outstanding
38.9M
Float
29.9M
Restricted Shares
9.0M
Restricted Shares, %
23.16%

ProQR Therapeutics NV Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Daniel Anton de Boer

Website: http://www.proqr.com

Description: ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Employees: -